open access

Vol 69, No 6 (2018)
REVIEWS — Postgraduate Education
Published online: 2018-12-20
Submitted: 2018-06-29
Accepted: 2018-07-11
Get Citation

Endocrine complications of cancer immunotherapy

Aleksandra Król, Tomasz Gawlik, Barbara Jarząb
DOI: 10.5603/EP.a2018.0073
·
Pubmed: 30618030
·
Endokrynologia Polska 2018;69(6):722-733.

open access

Vol 69, No 6 (2018)
REVIEWS — Postgraduate Education
Published online: 2018-12-20
Submitted: 2018-06-29
Accepted: 2018-07-11

Abstract

Immunotherapy using monoclonal antibodies — checkpoint inhibitors — is a dynamically evolving discipline of clinical oncology and a new hope for patients with advanced and disseminated cancer. However, the activation of T-lymphocytes can at the same time lead to autoimmune response and destruction of healthy organs, which is a serious adverse effect that can also affect the endocrine system. Here we present possible endocrine complications of immunotherapy with contemporary inhibitors of immune checkpoints (CTLA-4, PD-1, PD-L1/L2), their frequency, symptoms, and proposed grade-dependent treatment.Failure to diagnose endocrine pathology can in adverse circumstances lead to treatment failure and condemn the patient’s fate. Due to tremendous progress in cancer immunotherapy during the last few years and an increase in the number of treated patients, endocrinologists should become acquainted with the specificity of this mode of oncological treatment.

Abstract

Immunotherapy using monoclonal antibodies — checkpoint inhibitors — is a dynamically evolving discipline of clinical oncology and a new hope for patients with advanced and disseminated cancer. However, the activation of T-lymphocytes can at the same time lead to autoimmune response and destruction of healthy organs, which is a serious adverse effect that can also affect the endocrine system. Here we present possible endocrine complications of immunotherapy with contemporary inhibitors of immune checkpoints (CTLA-4, PD-1, PD-L1/L2), their frequency, symptoms, and proposed grade-dependent treatment.Failure to diagnose endocrine pathology can in adverse circumstances lead to treatment failure and condemn the patient’s fate. Due to tremendous progress in cancer immunotherapy during the last few years and an increase in the number of treated patients, endocrinologists should become acquainted with the specificity of this mode of oncological treatment.

Get Citation

Keywords

immunotherapy; immune checkpoints inhibitors; endocrine complications

About this article
Title

Endocrine complications of cancer immunotherapy

Journal

Endokrynologia Polska

Issue

Vol 69, No 6 (2018)

Pages

722-733

Published online

2018-12-20

DOI

10.5603/EP.a2018.0073

Pubmed

30618030

Bibliographic record

Endokrynologia Polska 2018;69(6):722-733.

Keywords

immunotherapy
immune checkpoints inhibitors
endocrine complications

Authors

Aleksandra Król
Tomasz Gawlik
Barbara Jarząb

References (39)
  1. Farkona S, Diamandis EP, Blasutig IM. Cancer immunotherapy: the beginning of the end of cancer? BMC Med. 2016; 14: 73.
  2. Joshi M, Pal SK, Drabick JJ. Novel approaches in cancer immunotherapy — a light at the end of the tunnel. Discov Med. 2016; 21(118): 479–487.
  3. Heymach J, Krilov L, Alberg A, et al. Clinical Cancer Advances 2018: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology. J Clin Oncol. 2018; 36(10): 1020–1044.
  4. Li X, Shao C, Shi Y, et al. Lessons learned from the blockade of immune checkpoints in cancer immunotherapy. Hematol Oncol. 2018; 11(31): 1–26.
  5. Wang Ke, Zhu Q, Lu Y, et al. CTLA-4 +49 G/A Polymorphism Confers Autoimmune Disease Risk: An Updated Meta-Analysis. Genet Test Mol Biomarkers. 2017; 21(4): 222–227.
  6. Chen Z, Fei M, Fu Da, et al. Association between cytotoxic T lymphocyte antigen-4 polymorphism and type 1 diabetes: a meta-analysis. Gene. 2013; 516(2): 263–270.
  7. Houcken J, Degenhart C, Bender K, et al. PTPN22 and CTLA-4 Polymorphisms Are Associated With Polyglandular Autoimmunity. J Clin Endocrinol Metab. 2018; 103(5): 1977–1984.
  8. Tokić S, Štefanić M, Karner I, et al. Altered expression of CTLA-4, CD28, VDR, and CD45 mRNA in T cells of patients with Hashimoto's thyroiditis — a pilot study. Endokrynol Pol. 2017; 68(3): 274–828.
  9. Gu Lq, Zhu W, Zhao Sx, et al. Clinical associations of the genetic variants of CTLA-4, Tg, TSHR, PTPN22, PTPN12 and FCRL3 in patients with Graves' disease. Clin Endocrinol (Oxf). 2010; 72(2): 248–255.
  10. Cranmer LD, Hersh E. The role of the CTLA4 blockade in the treatment of malignant melanoma. Cancer Invest. 2007; 25(7): 613–631.
  11. Dudnik E, Peled N, Nechushtan H, et al. Israel Lung Cancer Group. BRAF Mutant Lung Cancer: Programmed Death Ligand 1 Expression, Tumor Mutational Burden, Microsatellite Instability Status, and Response to Immune Check-Point Inhibitors. J Thorac Oncol. 2018; 13(8): 1128–1137.
  12. Teixidó C, Vilariño N, Reyes R, et al. PD-L1 expression testing in non-small cell lung cancer. Ther Adv Med Oncol. 2018; 10: 1758835918763493.
  13. Du W, Yang M, Turner A, et al. TIM-3 as a Target for Cancer Immunotherapy and Mechanisms of Action. Int J Mol Sci. 2017; 18(3): 645.
  14. Imai Y, Hasegawa K, Matsushita H, et al. Expression of multiple immune checkpoint molecules on T cells in malignant ascites from epithelial ovarian carcinoma. Oncol Lett. 2018; 15(5): 6457–6468.
  15. June CH, Warshauer JT, Bluestone JA. Is autoimmunity the Achilles' heel of cancer immunotherapy? Nat Med. 2017; 23(5): 540–547.
  16. Valpione S, Pasquali S, Campana LG, et al. Sex and interleukin-6 are prognostic factors for autoimmune toxicity following treatment with anti-CTLA4 blockade. J Transl Med. 2018; 16(1): 94.
  17. Anderson R, Rapoport BL. Immune Dysregulation in Cancer Patients Undergoing Immune Checkpoint Inhibitor Treatment and Potential Predictive Strategies for Future Clinical Practice. Front Oncol. 2018; 8: 80.
  18. Calles A, Liao X, Sholl LM, et al. Expression of PD-1 and Its Ligands, PD-L1 and PD-L2, in Smokers and Never Smokers with KRAS-Mutant Lung Cancer. J Thorac Oncol. 2015; 10(12): 1726–1735.
  19. Humphries A, Daud A. The gut microbiota and immune checkpoint inhibitors. Hum Vaccin Immunother. 2018; 14(9): 2178–2182.
  20. Rapoport BL, van Eeden R, Sibaud V, et al. Supportive care for patients undergoing immunotherapy. Support Care Cancer. 2017; 25(10): 3017–3030.
  21. Sosa A, Lopez Cadena E, Simon Olive C, et al. Clinical assessment of immune-related adverse events. Ther Adv Med Oncol. 2018; 10: 1–11.
  22. Michot JM, Bigenwald C, Champiat S, et al. Immune-related adverse events with immune checkpoint blockade: a comprehensive review. Eur J Cancer. 2016; 54: 139–148.
  23. Horvat TZ, Adel NG, Dang TO, et al. Immune-Related Adverse Events, Need for Systemic Immunosuppression, and Effects on Survival and Time to Treatment Failure in Patients With Melanoma Treated With Ipilimumab at Memorial Sloan Kettering Cancer Center. J Clin Oncol. 2015; 33(28): 3193–3198.
  24. Massard C, Gordon MS, Sharma S, et al. Safety and Efficacy of Durvalumab (MEDI4736), an Anti-Programmed Cell Death Ligand-1 Immune Checkpoint Inhibitor, in Patients With Advanced Urothelial Bladder Cancer. J Clin Oncol. 2016; 34(26): 3119–3125.
  25. Antonia SJ, Villegas A, Daniel D, et al. PACIFIC Investigators. Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer. N Engl J Med. 2017; 377(20): 1919–1929.
  26. Johnston RL, Lutzky J, Chodhry A, et al. Cytotoxic T-lymphocyte-associated antigen 4 antibody-induced colitis and its management with infliximab. Dig Dis Sci. 2009; 54(11): 2538–2540.
  27. Kim HIn, Kim M, Lee SH, et al. Development of thyroid dysfunction is associated with clinical response to PD-1 blockade treatment in patients with advanced non-small cell lung cancer. Oncoimmunology. 2017; 7(1).
  28. Cukier P, Santini FC, Scaranti M, et al. Endocrine side effects of cancer immunotherapy. Endocr Relat Cancer. 2017; 24(12): T331–T347.
  29. Stangierski A, Ruchała M, Krauze T, et al. Treatment of severe thyroid function disorders and changes in body composition. Endokrynol Pol. 2016; 67(4): 359–366.
  30. Faje AT, Sullivan R, Lawrence D, et al. Ipilimumab-induced hypophysitis: a detailed longitudinal analysis in a large cohort of patients with metastatic melanoma. J Clin Endocrinol Metab. 2014; 99(11): 4078–4085.
  31. Albarel F, Gaudy C, Castinetti F, et al. Long-term follow-up of ipilimumab-induced hypophysitis, a common adverse event of the anti-CTLA-4 antibody in melanoma. Eur J Endocrinol. 2015; 172(2): 195–204.
  32. Bronstein Y, Ng CS, Hwu P, et al. Radiologic manifestations of immune-related adverse events in patients with metastatic melanoma undergoing anti-CTLA-4 antibody therapy. AJR Am J Roentgenol. 2011; 197(6): W992–W1000.
  33. Tirumani SH, Ramaiya NH, Keraliya A, et al. Radiographic Profiling of Immune-Related Adverse Events in Advanced Melanoma Patients Treated with Ipilimumab. Cancer Immunol Res. 2015; 3(10): 1185–1192.
  34. Haanen J, Carbonnel F, Robert C, et al. Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†. Annals of Oncology. 2017; 28(Suppl 4): iv119–iv142.
  35. Corsello S, Barnabei A, Marchetti P, et al. Endocrine Side Effects Induced by Immune Checkpoint Inhibitors. Clin Endocrinol Metab. 2013; 98(4): 1361–1375.
  36. González-Rodríguez E, Rodríguez-Abreu D. Spanish Group for Cancer Immuno-Biotherapy (GETICA). Immune Checkpoint Inhibitors: Review and Management of Endocrine Adverse Events. Oncologist. 2016; 21(7): 804–816.
  37. Robert C, Long GV, Brady B, et al. Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med. 2015; 372(4): 320–330.
  38. Ribas A, Hamid O, Daud A, et al. Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced Melanoma. JAMA. 2016; 315(15): 1600–1609.
  39. Win MA, Thein KZ, Qdaisat A, et al. Acute symptomatic hypocalcemia from immune checkpoint therapy-induced hypoparathyroidism. Am J Emerg Med. 2017; 35(7): 1039.e5–1039.e7.

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Via MedicaWydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl